Join Now!

Begin our membership application process today!

Contact Us                                                                                                        

Kena Norris
Executive Director

312.227.7406
knorris@ccpapp.org

Priya Stemler
Director of Operations

312.227.7437
pstemler@ccpapp.org

Paresh Patel
National Sales Manager

312.227.7436
papatel@ccpapp.org

Jennifer Jackson
Sr. Administrative Assistant
312.227.7442
jdjackson@ccpapp.org
 
Sonia Perez Gandara
Member Relations Specialist

312.227.7508
sgandara@ccpapp.org

General Inquiries:
312.227.7444
info@ccpapp.org
 
 

MMWR Published ACIP Recommendation on Use of Serogroup B Meningococcal (MenB) Vaccines (October 2015)

MMWR Published ACIP Recommendation on Use of Serogroup B Meningococcal (MenB) Vaccines

In October 2015, the Morbidity and Mortality Weekly Report (MMWR) published the June 24, 2015 Advisory Committee on Immunization Practices (ACIP) recommendation stating that the Serogroup B Meningococcal (MenB) vaccination series may be administered to individuals between the ages of 16 through 231

The recommendation is as follows:

Advisory Committee on Immunization Practices (ACIP) recommends that a MenB vaccine series may be administered to adolescents and young adults aged 16 through 23 years to provide short-term protection against most strains of MenB disease. The preferred age for MenB vaccination is 16 through 18 years. The recommendation is labeled as Category B meaning that individual clinical decision making is recommended.

To view the October 23, 2015 MMWR publication, click here.

This recommendation is in addition to the existing Category A Serogroup B Meningococcal vaccine recommendation for individuals aged ≥ 10 years at increased risk for meningococcal disease, published in the June 12, 2015 edition of the MMWR (click here to view).

Please note that The Affordable Care Act ensures insurance coverage for all ACIP-recommended vaccinations including Category B ACIP recommendations.  Healthcare providers should contact their individual plan to determine specific coverage and reimbursement requirements and adoption timeframes.2 Serogroup B Meningococal vaccines are available through the Vaccines for Children program.3

For questions regarding any of the above information and/or participation in the CCPAPP-Pfizer agreement for Trumenba, please contact Scott Jablonski, Vaccine Account Manager for Pfizer, at 708.990.6335 or scott.r.jablonkski@pfizer.com. You may also contact Priya Stemler, Director of Operations for CCPAPP, at 312.227.7437 or pstemler@ccpapp.org

1. Centers for Disease Control and Prevention. Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(41);1171-6. 2. The Center for Consumer Information & Insurance Oversight. Affordable Care Act Implementation FAQs - Set 12. CMS.gov Web site. http://www.cms.gov/CCIIO/Resources/Fact-Sheets-and-FAQs/aca_implementation_faqs12.html. Accessed July 23, 2015. 3. Centers for Disease Control and Prevention. Vaccines for Children Resolution No. 6/15-1. Vaccines to Prevent Meningococcal Disease. Atlanta, GA: Centers for Disease Control and Prevention; June 24, 2015.

 

« Back

 
 

 

 

logo_Merck[1]

header_logo_sp[1]

 

 

LOGO_MMS

 

 

 

 
Copyright © 2019 CCPA Purchasing Partners. All rights reserved.
Web site design and development by Americaneagle.com